简体中文
|
English
HOME
ABOUT US
Introduction
Company Culture
Management Team
RESEARCH CENTER
Product Pipelines
ADC Technology
NEWS AND MEDIA
CAREERS
CONTACT US
HOME
ABOUT US
RESEARCH CENTER
NEWS AND MEDIA
CAREERS
CONTACT US
NEWS AND MEDIA
Home
NEWS AND MEDIA
2023.12.01
Expanded Access Policy
02/05
2021
On Feb 5, 2021, MRG004A received IND clearance for Phase I/II clinical study from the US FDA.
01/08
2021
2021.01 MRG004A IND submission formally accepted by the FDA
10/19
2020
Claudin 18.2 Targeted ADC, which is jointly developed by Shanghai Miracogen Inc. and Chengdu ConMed Biosciences Inc., was approved by NMPA on October 19, 2020 for a phase I clinical study.
10/06
2020
EGFR-targeted ADC was granted a Chinese patent on June 19, 2020 and a US patent on October 6, 2020.
05/11
2020
MRG002 completed an IND application in the United States on April 10, 2020 and approved by the US FDA for a phase I/II clinical study of HER2-positive gastric/gastroesophageal and pharyngeal junction cancer on May 11, 2020.
FIRST
Previous page
1
2
3
4
next page
END